OncoMatch/Clinical Trials/NCT06047886

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

Is NCT06047886 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Infusion of CD34 selected hematopoietic stem cells for aml.

Treatment: Infusion of CD34 selected hematopoietic stem cells — Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature. Therefore those patients are at increased risk of graft versus host disease, and the infusion of a CD34 selected graft would reduce such a risk. The infusion of CD34 selected graft using CliniMACS plus is currently FDA FDA-approved indication for acute myeloid leukemia. However, the use of the Prodigy would streamline the processing, in terms of hands-off procedure, allowing to provision of this product to the patients without strains on the cell therapy lab team. This procedure has been demonstrated safe and effective in several single-center studies and is currently in advanced phase investigation in several studies for malignant and non-malignant conditions.